Artivion (NYSE:AORT) Trading Up 5.7% – Here’s Why

Shares of Artivion, Inc. (NYSE:AORT) traded up 5.7% during mid-day trading on Tuesday . The stock traded as high as $29.35 and last traded at $29.94. Approximately 91,970 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 592,308 shares. The stock had previously closed at $28.32.

Analysts Set New Price Targets

AORT has been the subject of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $44.00 price target on shares of Artivion in a report on Monday, July 20th. Citigroup reissued a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Canaccord Genuity Group upped their target price on Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Artivion currently has an average rating of “Moderate Buy” and a consensus price target of $44.83.

Artivion Price Performance

The stock has a market capitalization of $1.44 billion, a P/E ratio of -423.94 and a beta of 1.24. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The business’s 50 day simple moving average is $24.44 and its two-hundred day simple moving average is $30.41.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The business had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. As a group, sell-side analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jean F. Holloway sold 977 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the sale, the senior vice president owned 184,118 shares of the company’s stock, valued at $5,245,521.82. This trade represents a 0.53% decrease in their position. The SEC filing for this sale provides additional information. 6.30% of the stock is owned by company insiders.

Institutional Trading of Artivion

Institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new position in shares of Artivion during the third quarter valued at about $27,000. Rockefeller Capital Management L.P. boosted its holdings in Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares during the last quarter. Larson Financial Group LLC grew its position in Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares in the last quarter. Smartleaf Asset Management LLC grew its position in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares in the last quarter. Finally, KBC Group NV purchased a new stake in Artivion in the 4th quarter valued at about $65,000. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.